Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

Chronic kidney disease (CKD) is a major public health problem that has received increasing attention because of the high rate of associated cardiovascular morbidity and mortality. Mounting evidence indicates that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) safely slow down progression of CKD. There is also growing evidence supporting combination treatment of nephropathies with an ACE inhibitor plus an ARB to more completely block the RAAS and provide greater renoprotection than either an ACE inhibitor-based or ARB-based regimen. The National Kidney Foundation suggests that ACE inhibitors and ARBs may be used in combination to reduce proteinuria in patients with kidney disease; however, larger outcomes trials are needed.

Original languageEnglish (US)
Pages (from-to)372-380
Number of pages9
JournalAmerican Journal of Nephrology
Volume28
Issue number3
DOIs
StatePublished - Apr 2008

Keywords

  • Angiotensin receptor blocker
  • Angiotensin-converting enzyme inhibitor
  • Chronic kidney disease
  • Combination therapy
  • Renin-angiotensin-aldosterone system

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this